Home LiteratureArticle Details
PMID: 20576095 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Breast cancer research : BCR ·Vol. 12 ·No. 3 ·2010-00-00 ·Pages R42

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A

Abstract

Breast cancer is a profoundly heterogeneous disease with respect to biologic and clinical behavior. Gene-expression profiling has been used to dissect this complexity and to stratify tumors into intrinsic gene-expression subtypes, associated with distinct biology, patient outcome, and genomic alterations. Additionally, breast tumors occurring in individuals with germline BRCA1 or BRCA2 mutations typically fall into distinct subtypes. We applied global DNA copy number and gene-expression profiling in 359 breast tumors. All tumors were classified according to intrinsic gene-expression subtypes and included cases from genetically predisposed women. The Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm was used to identify significant DNA copy-number aberrations and genomic subgroups of breast cancer. We identified 31 genomic regions that were highly amplified in > 1% of the 359 breast tumors. Several amplicons were found to co-occur, the 8p12 and 11q13.3 regions being the most frequent combination besides amplicons on the same chromosomal arm. Unsupervised hierarchical clustering with 133 significant GISTIC regions revealed six genomic subtypes, termed 17q12, basal-complex, luminal-simple, luminal-complex, amplifier, and mixed subtypes. Four of them had striking similarity to intrinsic gene-expression subtypes and showed associations to conventional tumor biomarkers and clinical outcome. However, luminal A-classified tumors were distributed in two main genomic subtypes, luminal-simple and luminal-complex, the former group having a better prognosis, whereas the latter group included also luminal B and the majority of BRCA2-mutated tumors. The basal-complex subtype displayed extensive genomic homogeneity and harbored the majority of BRCA1-mutated tumors. The 17q12 subtype comprised mostly HER2-amplified and HER2-enriched subtype tumors and had the worst prognosis. The amplifier and mixed subtypes contained tumors from all gene-expression subtypes, the former being enriched for 8p12-amplified cases, whereas the mixed subtype included many tumors with predominantly DNA copy-number losses and poor prognosis. Global DNA copy-number analysis integrated with gene-expression data can be used to dissect the complexity of breast cancer. This revealed six genomic subtypes with different clinical behavior and a striking concordance to the intrinsic subtypes. These genomic subtypes may prove useful for understanding the mechanisms of tumor development and for prognostic and treatment prediction purposes.

MeSH Terms
Adult Aged Aged, 80 and over BRCA1 Protein/genetics BRCA2 Protein/genetics Biomarkers, Tumor/genetics,metabolism Breast Neoplasms/classification,genetics,pathology Comparative Genomic Hybridization Female Follow-Up Studies Gene Expression Profiling Genetic Predisposition to Disease Humans Middle Aged Mutation/genetics Neoplasms, Basal Cell/classification,genetics,pathology Oligonucleotide Array Sequence Analysis Prognosis Survival Rate
Chemicals
BRCA1 Protein BRCA2 Protein Biomarkers, Tumor
Authors & Affiliations
23 authors, click to expand affiliations / ORCID
Jönsson Göran
Department of Oncology, Clinical Sciences, Lund University and Skåne University Hospital, Barngatan 2B, 5 Lund, Sweden. [email protected]
Staaf Johan
Vallon-Christersson Johan
Ringnér Markus
Holm Karolina
Hegardt Cecilia
Gunnarsson Haukur
Fagerholm Rainer
Strand Carina
Agnarsson Bjarni A
Kilpivaara Outi
Luts Lena
Heikkilä Päivi
Aittomäki Kristiina
Blomqvist Carl
Loman Niklas
Malmström Per
Olsson Håkan
Johannsson Oskar Th
Arason Adalgeir
Nevanlinna Heli
Barkardottir Rosa B
Borg Ake
References (32)
32 references, click to expand
  1. The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
    Breast Cancer Res. 2008;10(3):R53 PMID: 18559090
  2. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.
    Oncogene. 2006 Oct 19;25(49):6544-53 PMID: 16702952
  3. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
    Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40 PMID: 16897746
  4. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry.
    Br J Cancer. 2004 Apr 5;90(7):1422-8 PMID: 15054466
  5. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  6. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.
    Cancer Res. 2004 Dec 1;64(23):8541-9 PMID: 15574760
  7. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation.
    Nucleic Acids Res. 2002 Feb 15;30(4):e15 PMID: 11842121
  8. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.
    Breast Cancer Res. 2005;7(6):R1186-98 PMID: 16457699
  9. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.
    Breast Cancer Res. 2008;10(6):R93 PMID: 19014521
  10. [''R"--project for statistical computing].
    Ugeskr Laeger. 2008 Jan 28;170(5):328-30 PMID: 18252159
  11. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
    Genes Chromosomes Cancer. 2007 Jun;46(6):543-58 PMID: 17334996
  12. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
    Cancer Cell. 2006 Dec;10(6):529-41 PMID: 17157792
  13. MYB oncogene amplification in hereditary BRCA1 breast cancer.
    Cancer Res. 2000 Oct 1;60(19):5323-8 PMID: 11034064
  14. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.
    Cancer Res. 2006 Nov 1;66(21):10292-301 PMID: 17079448
  15. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  16. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
    Breast Cancer Res. 2010;12(3):R25 PMID: 20459607
  17. Breast tumor copy number aberration phenotypes and genomic instability.
    BMC Cancer. 2006 Apr 18;6:96 PMID: 16620391
  18. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
    Cancer Res. 2002 Dec 1;62(23):7110-7 PMID: 12460933
  19. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
    N Engl J Med. 2009 Jul 9;361(2):123-34 PMID: 19553641
  20. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.
    Oncogene. 2009 Apr 30;28(17):1892-903 PMID: 19330026
  21. Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
    Clin Cancer Res. 2009 Apr 15;15(8):2711-22 PMID: 19318498
  22. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
    Oncogene. 2008 May 15;27(22):3165-75 PMID: 18071313
  23. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
    Cancer Res. 2005 Feb 1;65(3):822-7 PMID: 15705879
  24. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.
    EMBO J. 2009 Jul 8;28(13):1926-39 PMID: 19521340
  25. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Cancer Res. 2005 Apr 1;65(7):2554-9 PMID: 15805248
  26. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
    Int J Cancer. 2006 Sep 1;119(5):1052-60 PMID: 16570289
  27. A faster circular binary segmentation algorithm for the analysis of array CGH data.
    Bioinformatics. 2007 Mar 15;23(6):657-63 PMID: 17234643
  28. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
    Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 PMID: 18077431
  29. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    J Clin Oncol. 2010 Apr 10;28(11):1813-20 PMID: 20231686
  30. The molecular portraits of breast tumors are conserved across microarray platforms.
    BMC Genomics. 2006 Apr 27;7:96 PMID: 16643655
  31. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
    Cancer Res. 2005 Sep 1;65(17):7612-21 PMID: 16140926
  32. Normalization of array-CGH data: influence of copy number imbalances.
    BMC Genomics. 2007 Oct 22;8:382 PMID: 17953745
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2010-00-00
Epub
2010-00-24
Pages
R42
Language
English
Region
England
NLM ID
100927353
PMCID
PMC2917037
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]